Thus, blocking PD-1 and PD-L1 can activate antitumor activity through activation of T-cells and inhibition of Treg cells, and it can also promote CD4+T cell differentiation into FOX P3+ Tregs by enhancing suppression of the immune system, resulting in immune tolerance in cancer patients [160]. This evidence concerns the gene PDCD1 and cancer.